Quick Answer
Esperion Therapeutics, Inc. reported Stockholders Equity of -$301.97 million for the year ending 2025.
- Esperion Therapeutics, Inc. showed an increase of +22.3% in Stockholders Equity from 2024 to 2025.
- This data is from Esperion Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 10, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2014: $67.04 million | Q2 2014: $58.91 million | Q3 2014: $50.22 million | Q1 2015: $314.43 million | Q2 2015: $305.46 million | Q3 2015: $296.48 million | Q1 2016: $277.76 million | Q2 2016: $267.96 million | Q3 2016: $254.18 million | Q1 2017: $192.42 million | Q2 2017: $154.11 million | Q3 2017: $278.10 million | Q1 2018: $214.14 million | Q2 2018: $175.92 million | Q3 2018: $131.75 million | Q1 2019: $175.01 million | Q2 2019: $129.33 million | Q3 2019: $68.51 million | Q1 2020: -$50.25 million | Q2 2020: $85.49 million | Q3 2020: $8.96 million | Q1 2021: -$269.39 million | Q2 2021: -$304.31 million | Q3 2021: -$362.71 million | Q1 2022: -$249.04 million | Q2 2022: -$291.70 million | Q3 2022: -$294.10 million | Q1 2023: -$329.66 million | Q2 2023: -$371.98 million | Q3 2023: -$410.00 million | Q1 2024: -$294.30 million | Q2 2024: -$344.22 million | Q3 2024: -$370.21 million | Q1 2025: -$426.21 million | Q2 2025: -$433.51 million | Q3 2025: -$451.36 million.
- Over the full 16 years of available data (2010 to 2025), Esperion Therapeutics, Inc.'s Stockholders Equity has declined by 1,463.5%.
- Historical annual values: Fiscal year 2025: -$301.97 million | Fiscal year 2024: -$388.72 million | Fiscal year 2023: -$454.99 million | Fiscal year 2022: -$323.78 million | Fiscal year 2021: -$196.94 million | Fiscal year 2020: -$96.13 million | Fiscal year 2019: $19.95 million | Fiscal year 2018: $79.12 million | Fiscal year 2017: $244.69 million | Fiscal year 2016: $228.60 million | Fiscal year 2015: $287.26 million | Fiscal year 2014: $133.55 million | Fiscal year 2013: $74.09 million | Fiscal year 2012: -$41.37 million | Fiscal year 2011: -$30.03 million | Fiscal year 2010: -$19.31 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: